CAM
PSTX

Cormorant Asset Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Cormorant Asset Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,000,000
Closed -$3.08M – 79
2023
Q1 		$3.08M Sell
1,000,000
-150,000
-13% -$899K 0.2% 56
2022
Q4 		$6.09M Sell
1,150,000
-700,000
-38% -$3.2M 0.41% 52
2022
Q3 		$6.53M Buy
+1,850,000
New +$6.12M 0.46% 49

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Cormorant Asset Management's PSTX Position: Q2 2023 in Review

Cormorant Asset Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2023, closing a stake of 1,000,000 shares — an estimated $3.08M sold.

Cormorant Asset Management first reported a position in PSTX in Q3 2022 and held it in 3 quarters. The position peaked at $6.53M in Q3 2022. 94 funds tracked by Wall St. Rank hold PSTX as of Q2 2023.

  • Cormorant Asset Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Cormorant Asset Management sold 1,000,000 Poseida Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $3.08M.
  • Cormorant Asset Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
  • Cormorant Asset Management's Poseida Therapeutics, Inc. Common Stock position peaked at $6.53M in Q3 2022.
  • 94 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Cormorant Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.